Lodotra is a proprietary, programmed-release formulation of low-dose prednisone and has received regulatory approval in Europe for the treatment of moderate to severe active rheumatoid arthritis (RA) when accompanied by morning stiffness.
The commercialization will happen in Mexico, Brazil, Argentina, Colombia, Venezuela, Peru, Chile, Ecuador, Dominican Republic, Guatemala, Costa Rica, Uruguay, Bolivia, Panama, Nicaragua, El Salvador and Honduras.
Mundipharma Asia Pacific & Latin America regional managing director Raman Singh said Lodotra represents an important advance in the improvement of outcomes and the quality of life for rheumatoid arthritis patients.
"We are excited about the addition of LODOTRA to our existing product portfolio in Latin America," Singh said.